Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy (METASUN)

Inclusion Criteria:

• Woman or man ≥ 18 Years old, histologically proven metastatic clear cell (or al least clear cell predominant) RCC,
• Good or intermediate risk according to MSKCC-criteria, Subjects falling into conditions for reimbursement of sunitinib or pazopanib in the context of mRCC,
• Measurable disease based on RECIST criteria (version 1.1) , Subject has given voluntary written informed consent,
• Subject is in the investigator's opinion, willing and able to comply with the protocol requirements, Subject has an ECOG ≤ 2,
• Subject with a life expectancy ≥ 3 months,
• Concurrent treatment with bisphosphonates and denosumab is allowed however it should have been started before screening of the study. If possible starting new medications between the baseline metabolo- and lipidomotype- and the first metabolo- and lipidomotypeanalysis should be avoided,
• Subjects having recovered from side effects from previous therapies to a grade 1 CTC vs 4.0 criteria

Exclusion Criteria:

• Patients with non-clear cell RCC and/or with sarcomatoid differentiation,
• Patients presenting any other type of cancer disease within 5 years from inclusion into this study; in the absence of cervical cancer or basocellular carcinoma, Patients with uncontrolled arterial hypertension,
• Patients with uncontrolled hypo- or hyperthyroidism,
• Patient had major surgery within 4 weeks before enrolment,
• Patient with myocardial infarction within 6 months prior enrolment or with NHYA class III otr IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia or electrocardiographic evidence of acute ischemia or active conduction system abnormalities,
• Patient has another serious medical condition that could potentially interfere with the completion of study,
• Sero-positive for HIV, Subject known to be hepatitis B surface antigen positive or who has an active hepatitis C infection,
• Subject has an active systemic infection requiring treatment,
• Female subject is pregnant or breast feeding, Subject enrolled in another clinical trial and/or receiving an investigational agent.